BACKGROUND: The European Union Summary of Product Characteristics (EU SmPC) for alemtuzumab in multiple sclerosis (MS) was revised in January 2020 under an Article 20 EU-pharmacovigilance procedure to include a revised indication, additional contraindications, and new monitoring requirements. OBJECTIVES: To evaluate adherence to the revised SmPC for alemtuzumab across four European countries.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Sanofi
Contact Sanofi, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack